Inmedix, a leader in the field of stress-related immune dysfunction research, has been voted as the "Most Valued Company" at the Keiretsu Forum Investor Capital Expo held in April 2025. The recognition highlights Inmedix’s pioneering work in harnessing cloud-based diagnostics and AI-driven insights to improve autoimmune disease management.
The Investor Capital Expo, hosted by Keiretsu Forum, the world’s largest angel investor network, brought together hundreds of investors, entrepreneurs, and industry leaders. The event provided a platform for high-potential startups to showcase groundbreaking innovations across various sectors. Inmedix stood out for its transformative approach to addressing chronic disease through its patented stress-immune diagnostics platform, drawing significant investor interest and acclaim.
Inmedix is revolutionizing the understanding and treatment of autoimmune diseases by integrating stress assessment into clinical care. Its proprietary technology, the Inmedix CloudHRV™, measures heart rate variability (HRV) to assess autonomic nervous system (ANS) function—an essential but often overlooked factor in immune system regulation. By providing real-time data and predictive analytics, Inmedix enables physicians to personalize treatments for conditions such as rheumatoid arthritis, lupus, and multiple sclerosis, improving patient outcomes and reducing healthcare costs.
“We are incredibly honored to receive this recognition at the Keiretsu Forum Investor Capital Expo,” said Andrew J. Holman, CEO and Co-founder of Inmedix. “This award is a reflection of the dedication of our team and the growing recognition of stress-immune dysfunction as a critical factor in chronic disease. We are excited to continue advancing our technology to empower physicians and improve patient care worldwide.”
The Most Valued Company award underscores the strong investor confidence in Inmedix’s vision and potential for long-term impact. With this recognition, Inmedix continues to gain momentum among healthcare professionals, investors, and strategic partners as it advances its innovative diagnostic solutions.
About Inmedix:
Inmedix is at the forefront of stress-immune diagnostics, leveraging cloud technology and AI-driven insights to enhance the diagnosis and treatment of autoimmune diseases. Through its patented Inmedix CloudHRV™ platform, the company provides clinicians with critical data on autonomic nervous system function, enabling personalized treatment strategies for chronic conditions. By addressing the role of stress in immune dysfunction, Inmedix aims to transform autoimmune disease management and improve patient outcomes. For more information, please visit www.inmedix.com.
About Keiretsu Forum:
Keiretsu Forum is the world's largest angel investor network, with over 3,000 accredited investor members across 50+ chapters on three continents. The forum provides entrepreneurs with access to capital, mentorship, and a global network of investors and partners. The Investor Capital Expo is the premier event for connecting investors with high-quality emerging companies.
